Lakefront Biotherapeutics NV(DE:GXE)
€30.14-0.86 (-2.77%)
DE:GXE
Lakefront Biotherapeutics NV earnings date
€30.14
At close:-0.86 (-2.77%)
Lakefront Biotherapeutics NV (GXE) Q4 2022 Earnings Report
6 Followers
DE:GXE Q4 2022 EPS Results
- Actual EPS
- -EUR 3.15
- Consensus EPS
- -EUR 0.63
- Beat/Miss
- Missed by -EUR 2.52
- One Year Ago EPS
- EUR 0.25
DE:GXE Q4 2022 Revenue Results
- Actual Revenue
- EUR 95.12M
- Expected Revenue
- EUR 125.97M
- Beat/Miss
- Missed by -EUR 30.85M
- YoY Revenue Growth
- -43.04%
Earnings Announcement Details
- Quarter
- Q4 2022
- Date
- 02/23/2023
- Time
- After Close
- Conference Call
- Thursday, February 23, 2023
DE:GXE Upcoming Earnings
Lakefront Biotherapeutics NV's next earnings date is estimated for February 24, 2027, based on past reporting schedules.
Q4 2022 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q4 2022 Earnings Slide Deck
No slide deck is available for this earnings event.
Q4 2022 Earnings Call Summary
No earnings call summary is available for this earnings event.
DE:GXE Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 24, 2027 | 2026 (Q4) | -0.66- | 11.87 | ― | ― |
| Nov 11, 2026 | 2026 (Q3) | -0.33-0.04 | -3.07 | 98.70% (+3.03) | |
| Aug 10, 2026 | 2026 (Q2) | -0.700.03 | -1.58 | 101.90% (+1.61) | |
| May 06, 2026 | 2026 (Q1) | -0.810.21 | -2.35 | 108.94% (+2.56) | |
| Feb 23, 2026 | 2025 (Q4) | ―11.87 | 0.29 | 4007.27% (+11.58) | |
| Nov 05, 2025 | 2025 (Q3) | -0.41-3.07 | -0.74 | -314.86% (-2.33) | |
| Jul 23, 2025 | 2025 (Q2) | -0.20-1.58 | 0.07 | -2357.14% (-1.65) | |
| Apr 23, 2025 | 2025 (Q1) | -0.14-2.35 | 0.36 | -752.78% (-2.71) | |
| Feb 12, 2025 | 2024 (Q4) | -0.510.29 | 2.39 | -87.91% (-2.10) | |
| Oct 30, 2024 | 2024 (Q3) | -0.15-0.74 | 0.39 | -289.74% (-1.13) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
